Notice of Results

Creo Medical Group PLC

05 September 2023

 

Creo Medical Group plc

("Creo" the "Company" or the "Group")

Notice of Interim Results

Investor Presentation

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, will announce its interim results for the six months ended 30 June 2023 on Tuesday, 12 September 2023.

Investor Presentation

Craig Gulliford, Chief Executive Officer, and Richard Rees, Chief Financial Officer, will provide a live presentation covering the interim results via the Investor Meet Company platform on Tuesday, 12 September 2023 at 17:00 BST.

The presentation is open to all existing/potential shareholders and analysts. Questions can be submitted at any time during the live presentation.

Investors can sign up to Investor Meet Company at no additional cost and register in advance to meet Creo Medical Group plc via: https://www.investormeetcompany.com/creo-medical-group-plc/register-investor

Investors who already follow Creo Medical Group plc on the Investor Meet Company platform will automatically be invited.

-Ends-

Enquiries:

Creo Medical Group plc	www.creomedical.com
Richard Rees (CFO)	[phone]
Cenkos Securities plc	[phone]
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson / Russell Kerr (Joint Broker)
Numis Securities Limited (Joint Broker)	[phone]
Freddie Barnfield / Duncan Monteith / Euan Brown
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus / Sam Allen / Phillip Marriage	Mob: [phone]

About Creo Medical 

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures.

For more information, please refer to the website www.creomedical.com

 

END